Skip to main content
Article
Attitudes and behavior of peripheral arterial disease patients toward influencing their physician's prescription of cholesterol-lowering medication
Preventive and Behavioral Medicine Publications and Presentations
  • Mary McGrae McDermott, Northwestern University
  • Kathleen M. Mazor, University of Massachusetts Medical School
  • George W. Reed, University of Massachusetts Medical School
  • Sherry L. Pagoto, University of Massachusetts Medical School
  • Rex Graff, Northwestern University
  • Philip A. Merriam, University of Massachusetts Medical School
  • Melina Kibbe, Jesse Brown Veterans Administration Medical Center
  • Philip Greenland, Northwestern University
  • Judith K. Ockene, University of Massachusetts Medical School
  • Barbara C. Olendzki, University of Massachusetts Medical School
  • Huimin Tao, Northwestern University
  • Ira S. Ockene, University of Massachusetts Medical School
UMMS Affiliation
Meyers Primary Care Institute; Department of Medicine; Division of Preventive and Behavorial Medicine; Division of Cardiovascular Medicine; Clinical and Population Health Research
Date
4-2-2010
Document Type
Article
Subjects
Peripheral Vascular Diseases; Cholesterol, LDL; Anticholesteremic Agents; Patient Compliance
Abstract
Among 355 peripheral arterial disease (PAD) patients with low density lipoprotein cholesterol (LDL-C) levels >/= 70 mg/dl, we assessed knowledge regarding optimal LDL levels and the importance of LDL-C-lowering therapy. We also assessed PAD participants' behaviors and attitudes regarding their engagement with their physician in treatment decisions for LDL-C lowering. The average baseline LDL-C level of participants was 103.4 mg/dl +/- 30.7 mg/dl. Seventy-six percent of participants were taking at least one cholesterol-lowering medication. Sixty-six percent were unable to define their optimal LDL-C. Only 47% strongly agreed that their own actions and decisions could reduce their LDL-C. Just 29.8% were aware that patients who request specific medications from their physician were more likely to receive them, and 16% had asked their physician whether they should be taking more cholesterol-lowering medication. These findings suggest that further study is needed to identify effective interventions to educate PAD patients and their physicians about the importance of cholesterol-lowering therapy and to encourage PAD patients to participate with their physician in decisions regarding cholesterol-lowering treatment. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00217919.
Rights and Permissions
Citation: Vasc Med. 2010 Apr;15(2):83-90. Epub 2010 Jan 29. Link to article on publisher's site
Related Resources
Link to Article in PubMed
PubMed ID
20118170
Citation Information
Mary McGrae McDermott, Kathleen M. Mazor, George W. Reed, Sherry L. Pagoto, et al.. "Attitudes and behavior of peripheral arterial disease patients toward influencing their physician's prescription of cholesterol-lowering medication" Vol. 15 Iss. 2 (2010) ISSN: 1358-863X (Linking)
Available at: http://works.bepress.com/sherry_pagoto/3/